Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the official market launch of Zepzelca (lurbinectedin), a novel drug for the treatment of small-cell lung cancer (SCLC), in Hong Kong and Macau. Lurbinectedin, discovered and developed by Spain-based Pharma Mar, S.A. (MCE: PHM), is a selective inhibitor of oncogenic transcription that promotes tumor cell death and normalizes the tumor microenvironment.
Luye obtained exclusive rights to develop and commercialize lurbinectedin in China through a licensing agreement with Pharma Mar in April 2019. Conditionally approved in the U.S. for the treatment of SCLC in 2020, the drug has since received approval in numerous countries worldwide. It was granted marketing approval in Hong Kong and Macau in November and December of last year, respectively, to treat metastatic SCLC in patients whose tumors progressed during or after platinum-based chemotherapy. In June of the same year, it was awarded priority review status in mainland China.- Flcube.com
